Of interest, the non-covalent KRAS<sup>G12D</sup> targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside. This evidence concerns the gene KRAS and pancreatic neoplasm.